Jen Nwankwo, Ph.D.
About Jen Nwankwo, Ph.D.
Jen Nwankwo is the Founder & CEO of 1910 Genetics, known for her insights on AI in drug development and her leadership in biotech.
Jen Nwankwo: Founder & CEO
Jen Nwankwo is the Founder and CEO of 1910 Genetics. Under her leadership, the company leverages artificial intelligence to enhance research and development productivity in the pharmaceutical industry. Nwankwo's work aims to distinguish AI-powered companies in the competitive biotech landscape. Her strategic vision has driven the company forward, making significant impacts on the integration of AI within drug development processes.
JP Morgan 2024 Interview with Jen Nwankwo
In 2024, Jen Nwankwo was featured in a JP Morgan interview discussing the potential of AI to improve R&D productivity within drug development. She elaborated on the distinct ways 1910 Genetics utilizes AI to enhance their operations and shared her insights on the future of biotech, including mergers and acquisitions (M&A), the influence of big tech in pharma, and the potential for initial public offerings (IPOs) in the industry.
Jen Nwankwo on 'Touching Base' Podcast
Jen Nwankwo participated in an episode of the 'Touching Base' podcast where she discussed various topics including Alzheimer's Disease, monkey cloning, and the stock performance of Cytokinetics. This platform provided her with an opportunity to share her expertise and perspectives on pressing issues and emerging trends in the biotech and pharmaceutical sectors.
AI Meets Life Sci Podcast: Jen Nwankwo
Jen Nwankwo was featured in the 'AI Meets Life Sci' podcast alongside Microsoft representatives and other experts. The episode focused on uncovering hidden data gems and discussed the role of AI in biotech. Nwankwo highlighted the innovations at 1910 Genetics, a company backed by notable figures like Sam Altman, and how they are accelerating scientific discovery through advanced data analytics and AI technologies.
Jen Nwankwo Appointments and Leadership
Jen Nwankwo has made strategic leadership appointments at 1910 Genetics, including Dr. Shaan C. Gandhi as an Independent Board Director and Bridget Cole as Chief Scientific Officer. These appointments reflect the company's commitment to strengthening its leadership team and advancing its mission to leverage AI in drug development.